BPGAM
SAGE

BTG Pactual Global Asset Management’s Sage Therapeutics SAGE Stock Holding History

BTG Pactual Global Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,015
Closed -$628K – 81
2018
Q2 		$628K Buy
4,015
+442
+12% +$69.4K 0.18% 49
2018
Q1 		$576K Buy
+3,573
New +$607K 0.15% 51

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BTG Pactual Global Asset Management's SAGE Position: Q3 2018 in Review

BTG Pactual Global Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 4,015 shares — an estimated $628K sold.

BTG Pactual Global Asset Management first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $628K in Q2 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • BTG Pactual Global Asset Management reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 4,015 Sage Therapeutics shares in Q3 2018, an estimated $628K.
  • BTG Pactual Global Asset Management first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • BTG Pactual Global Asset Management's Sage Therapeutics position peaked at $628K in Q2 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.